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Abstract 
The purpose of this project was to synthesize analogs of the phospholipid 
phosphatidic acid (PA) for use in investigating protein-lipid binding interactions. Using 
multiple organic synthesis steps, we produced a phospholipid containing a shortened lipid 
tail with a terminal azide group. The azide tag was attached in order to allow for 
introduction of reporter groups such as fluorophores. These tags will allow us to track 
the interaction between a specific protein and phospholipid using techniques such as 
fluorescence resonance energy transfer (FRET). 
Introduction 
The cell membrane has multiple components including phospholipids and 
membrane proteins. Interactions between proteins and phospholipids are part of 
numerous physiological and pathophysiological events. Binding acts as a regulatory 
mechanism that causes proteins to dock onto the cell surface. This allows them to 
perform specific functions needed by the cell. Phosphatidic acid (P A) has been directly 
implicated in activities such as diabetic cardiomyopathy9 and protooncogene regulation4. 
PA is also involved in the immune response3, phospholipid biosythesis5, intracellular 
traffickingt, and cell proliferation2. Tracking the specific mechanism can help in 
studying diseases caused by malfunctions in some of these crucial cellular processes. To 
study these processes, we are developing phospholipid analogs with azide reactive tags 
attached at different locations of the phospholipid, including the head or tail group 
(Figure 1). These will serve as versatile probes for examining cellular events. 
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Figure 1. Target lipid probes containing azide tags at different locations. 
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The bioorthogonal reactivity of the azide group allows for specific modification 
within a complex biological environments. Use of core azide-tagged structures avoids X-
ray crystallography, where time-consuming studies are required to study each separate 
protein. One type of approach to analysis includes Fluorescence Resonance Energy 
Transfer (FRET). FRET can be used to study lipid organization upon protein binding. 
Binding of the protein leads to a change in the proximity of lipids, which can be detected 
by energy transfer between fluorescent dyes incorporated into the lipid structure. These 
studies can produce a better understanding of receptor-ligand associations at the cellular 
level. Information from these studies can also provide vital details for improving medical 
treatments to diseases through the development of multivalent lipid analogs. Multivalent 
ligands exhibit high affinity and specificity in protein binding6• Studying these types of 
ligands is important because their properties allow for avoidance of side effects during 
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treatment. Most side effects arise because of interfering proteins that bind the same 
ligand. 
Materials and Methods 
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The synthesis of the phospholipid analog with an incorporated azide tag required 
multiple steps of organic synthesis. The following is a detailed outline of each step in the 
process. 
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(S)-4-( (4-me'thoxybenzyloxy) methyl)-2,2-dimethyl-l,3-dioxolane (5) 
Sodium hydroxide (259 n1g, 0.00648 mol) was dissolved to 50 ml of DMF in a round 
bottom flask at 0 °C and placed under nitrogen. (S)-{2,2-dimethyl-l,3-dioxolan-4-
yl)methanol (4) was added to an additional funnel mounted onto the reaction flask. The 
solution dropped into the reaction slowly over 30 minutes. PMBCI (4-methoxy benzyl 
chloride) (.823 J..lL, .006 mol) was then added to the solution at room temperature. The 
reaction stirred overnight and was quenched with 50 ml of H20. This was extracted with 
2, 40 ml portions of dichloromethane. The organic layer was removed and dried with 
magnesium sulfate, filtered and rotavaped. Thin layered chromatography (TLC) analysis 
of the product was performed using 25% ethyl acetatelhexanes solution. The plate was 
treated with potassium permanganate which stained the product spots. The product was 
purified by column chromatography over silica gel with gradient elution from 20%-400/0 
ethyl acetatelhexanes. The product came out in fractions 7-11, and was rotovaped then 
placed on a high vacuum pump to yield a yellow oil (l.05g). 
(R)-3-( 4-methoxybenzyloxy) propane-l,2-diol (6) 
(S)-4-{{4-methoxybenzloxy) methyl)-2,2-dimethyl-l,3-dioxolane (5) was quenched with 
50 mL of saturated sodium bicarbonate. Then, we did an extraction with 2, 50 ml portion 
of methylene chloride. The organic layer was then dried with magnesium sulfate, 
filtered, and rotovaped. TLC analysis of the product was performed using 75% ethyl 
acetatelhexanes solution. The plate was treated with potassium permanganate which 
stained the product spots. The product was purified by column chromatography over 
silica gel with gradient elution from 75%-100% ethyl acetatelhexanes. The product came 
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out in fractions 14-24, and was rotovaped then placed on a high vacuum pump (.598g, 
680/0). 
8-Azidoctanoic acid (7) 
Bromooctonoic acid (450 mg, 2.02 mol) and sodium azide (262 mg, 4.03 mol) were 
combined with 20 mL ofDMF in a round bottom flask. The reaction flask was immersed 
in an oil bath and heated to 75°C. The reaction stirred overnight at room temperature. 
The product was then purified by column chromatography over silica gel with gradient 
elution from 1 %-3% methanol/dichloromethane/l % acetic acid. Fractions collected were 
rotovaped and then placed on a high vacuum pump to yield a yellow oil (0.157g, 42%). 
(S)-2-hydroxy-3-( 4-methoxybenzloxy) propyl 8-azidoctanoate (8) 
(R)-3-( 4-methoxybenzyloxy) propane-l ,2-diol (6) (200 mg, 945 }lmol), azidoctanoic acid 
(157mg, 848 }lmol), DCC (N,N'-Dicyclohexylcarbodiimide) (233 mg, 1.13 mmol), and 
DMAP (4-Dimethylaminopyridine) (138 mg, 1.13 mmol) were suspended in 15 mL of 
dichloromethane in a round bottom flask. The reaction stirred overnight at room 
temperature. The reaction mixture was quenched with water and extracted twice with 
dichloromethane, dried with magnesium sulfate, filtered through celite, and then 
rotovaped. TLC analysis was performed using 35% ethyl acetate/ hexane. The plate was 
treated with potassium permanganate which stained the product spots. The product was 
purified by column chromatography over silica gel with gradient elution from 10%-50% 
ethyl acetatelhexanes. The product came out in fractions 34-38, and was rotovaped and 
then placed on a high vacuum pump (227mg, 71 %). 
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1-(8-azidoctanoyloxy)-3-( 4-methoxybenzyloxy) propan-2-yl hexadecanoate (9) 
(S)-2-hydroxy-3-( 4-methoxybenzyloxy) propyl 8-azidoctanoate (8) (l16mg, 307 Ilmol), 
stearic acid (l30mg, 460 Ilmol), DCC (94.9mg, 460 Ilmol), and DMAP (l8.7mg, 153.3 
Ilmol) were suspended in 6 mL of dichloromethane in a round bottom flask. The reaction 
stirred overnight at room temperature and was extracted with dichloromethane and water. 
The organic layer was then dried with magnesium sulfate, filtered, and rotovaped. TLC 
analysis of the product was performed using 20% ethyl acetatelhexanes solution. The 
plate was treated with potassium permanganate which stained the product spots. The 
product was purified by column chromatography over silica gel with gradient elution 
from 200/0-30% ethyl acetate/hexanes. The product came out in fractions 8-10, and was 
rotovaped and then placed on a high vacuum pump (173mg, 87%). 
1-(8-azidoctanoyloxy)-3-hydroxypropan-2-yl hexadecanoate (10) 
1-(8-azidoctanoyloxy)-3-(4-methoxybenzyloxy) propan-2-yl hexadecanoate (9) (l73mg, 
267.4 Ilmol) and DDQ (2,3-Dichloro-5,6-dicyano-p-benzoquinone) (l21.4mg, 534.7 
Ilmol) were suspended in a solution of 5 mL of dichloromethane and 500 ilL of deionized 
water. The reaction stirred at room temperature for 2 hours and was then quenched with 
20 mL of sodium bicarbonate. The product was extracted using 50 mL of 
dichloromethane. The organic layer was then dried with magnesium sulfate, filtered, and 
rotovaped. TLC analysis of the product was performed using 10% ethyl acetatelhexanes 
solution. The plate was treated with potassium permanganate which stained the product 
spots. The product was purified by column chromatography over silica gel with gradient 
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elution from 20%-30% ethyl acetate/hexanes. The product came out in fractions 17-26, 
and was rotovaped and then placed on a high vacuum pump (80mg, 57%). 
The final steps for P A synthesis was installing the phosphate group. This required two 
steps: phosphotriester formation and deprotection. 
Figure 3. Installation of the Phosphate Head Group ofPA Analogs 2 
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Phosphotriester formation (11) 
1-(8-azidoctanoyloxy)-3-hydroxypropan-2-yl hexadecanoate (10) (80mg, 152.1 Jlmol), 
phosphoram (N, N-Diethyl-l,5-dihydo 2,4, 3-benzodioxaphosphepin-3-amine (109mg, 
456 Jlmol), tetrazole (31mg, 456 Jlmol), 0.75 mL of dichloromethane, and 0.75 mL of 
acetonitrile were combined in a flame-dried round bottom flask. The reaction flask was 
placed at 0 °C while stirring under nitrogen for 5 minutes. It was then removed and let 
stir at room temperature for three hours. We then added M-CPBA (chloroperoxy benzoic 
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acid) (78.7mg, 456 Jlmol), and let reaction mixture stir at room temperature under air for 
three hours. The product was extracted with 2x25 mL of dichloromethane and 25 mL of 
saturated sodium bicarbonate. The organic layer was then dried with magnesium sulfate, 
filtered, and rotovaped. TLC analysis of the product was performed using 25% ethyl 
acetatelhexanes solution. The plate was treated with potassium permanganate which 
stained the product spots. The product was purified by column chromatography over 
silica gel with gradient elution from 30%-50% ethyl acetatelhexanes. The product came 
out in fractions 22-25, and was rotovaped and then placed on a high vacuum pump 
(78mg, 720/0). 
Deprotection to P A analog 1 
The protected 2-tail (33.2mg, 0.048 mmol), TMS-Br (0.0441g, 0.2879 mnl01), and ImL 
of dichloromethane were combined in a round bottom flask and let stir under nitrogen at 
o °C for three hours. 1 mL of saturated sodium bicarbonate was added to the solution and 
let stir for 20 minutes. 1 mL of distilled water was used to quench and then solution was 
placed on rotovap to evaporate off the dichloromethane only. TLC analysis of the 
product was performed using 50% ethyl acetate/isopropanol solution. The plate was 
treated with phospray which stained the product spots. The product was purified by 
reverse column chromatography over silica gel with gradient elution from 0%-100% 
methanol/water. The product came out in fractions 4-6, and was rotovaped and then 
placed on a high vacuum pump (9.7mg, 33%). 
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One of the final parts of the experiment performed was synthesis of the 
fluorophore, anthracene, for FRET use. We followed the protocol outline by Owton et al. 
We added dropwise a solution of tetrabutylammonium bromide (4.93g, 15.3 mmol) and 
10 mL of deionized water to a solution of potassium permanganate (2.27 g, 14.4 mmol) in 
30 mL deionized water while continuously stirring. We let the solution stir for 1 hour at 
room temperature. The solution was filtered using a Buchner funnel. The solid removed 
was dissolved in 75 mL of pyridine. In another round bottom flask, a mixture of 2-
methyl anthraquinone (lg, 4.5 mmol) and 30 mL of pyridine was stirred and heated to 75 
°C under nitrogen. The tetrabutylammonium permanganate solution was added dropwise 
(over 1 hour) to the 2-methylanthraquinone solution. The reaction mixture was further 
stirred for 1 hour at 75°C. TLC analysis of the product was performed using 10% 
methanol/dichloromethane solution. The plate was observed under UV light which 
showed that the starting material was gone. The solution was cooled to 15°C and sodium 
metabisulfite (7.36g, 38.7 mmol) was added and let stir overnight at room temperature. 
The solution was rotovaped down and the residue was dissolved in 100 mL of deionized 
water. Concentrated HCI was added until we reached a pH of 4. The solution was then 
cooled down to 2°C, filtered, then placed on high vacuum'. 
Results and Discussion 
The final product was made and confirmed after a proton and phosphorous NMR. 
The overall yield of the synthesis was low because many steps were repeated due to the 
incorrect products formed. When making product (7), an additional purification step was 
done due to the observation of a solid impurity. The product was filtered with celite in 
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50/0 methanol/dichloromethane. During the purification of product (8), coupling product 
came out with the target product. This was confirmed using TLC analysis. The 
byproduct spot came out slightly below the target product (8) spot. TLC analysis with 
potassium permanganate sometimes yielded weak spots. TLC analysis was done again 
using a Ce/Mn stain. 
One part of this synthesis that we are continuing to work on is the deprotection 
step. We have not gotten consistent results or a good yield with the different approaches 
we have made to this reaction. We have often seen the absence of a peak after the 
phosphorous NMR. The product has also been unstable in the solvents we use, so it is 
hard to isolate. We have experimented with a methanol/water mixture and also a 
chloroform/methanol/water mixture. But the results still show a low product yield and no 
phosphorous peak. 
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